225 related articles for article (PubMed ID: 11106934)
1. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
3. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
Koido S; Tanaka Y; Chen D; Kufe D; Gong J
J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
[TBL] [Abstract][Full Text] [Related]
5. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
Koido S; Enomoto Y; Apostolopoulos V; Gong J
Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
[TBL] [Abstract][Full Text] [Related]
6. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
7. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice.
Chen D; Koido S; Li Y; Gendler S; Gong J
Breast Cancer Res Treat; 2000 Mar; 60(2):107-15. PubMed ID: 10845273
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
9. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells.
Gong J; Chen D; Kashiwaba M; Li Y; Chen L; Takeuchi H; Qu H; Rowse GJ; Gendler SJ; Kufe D
Proc Natl Acad Sci U S A; 1998 May; 95(11):6279-83. PubMed ID: 9600956
[TBL] [Abstract][Full Text] [Related]
10. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
11. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
12. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
13. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
14. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA.
Koido S; Kashiwaba M; Chen D; Gendler S; Kufe D; Gong J
J Immunol; 2000 Nov; 165(10):5713-9. PubMed ID: 11067929
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
16. CTL in mice immunized with human mucin 1 are MHC-restricted.
Apostolopoulos V; Loveland BE; Pietersz GA; McKenzie IF
J Immunol; 1995 Dec; 155(11):5089-94. PubMed ID: 7594517
[TBL] [Abstract][Full Text] [Related]
17. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
[TBL] [Abstract][Full Text] [Related]
18. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
19. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
20. Influence of organ site and tumor cell type on MUC1-specific tumor immunity.
Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA
Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]